KR920703839A - 신규의 유전자 및 폴리펩티드의 무세포 합성 및 분리 - Google Patents

신규의 유전자 및 폴리펩티드의 무세포 합성 및 분리

Info

Publication number
KR920703839A
KR920703839A KR1019920700769A KR920700769A KR920703839A KR 920703839 A KR920703839 A KR 920703839A KR 1019920700769 A KR1019920700769 A KR 1019920700769A KR 920700769 A KR920700769 A KR 920700769A KR 920703839 A KR920703839 A KR 920703839A
Authority
KR
South Korea
Prior art keywords
sequence
rna
cdna
interest
mrna
Prior art date
Application number
KR1019920700769A
Other languages
English (en)
Other versions
KR0185192B1 (ko
Inventor
가와사끼 글렌
Original Assignee
가와사끼 글렌
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 가와사끼 글렌 filed Critical 가와사끼 글렌
Publication of KR920703839A publication Critical patent/KR920703839A/ko
Priority to KR1019980708672A priority Critical patent/KR100204359B1/ko
Priority to KR1019980708673A priority patent/KR100204360B1/ko
Application granted granted Critical
Publication of KR0185192B1 publication Critical patent/KR0185192B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/12—Acyclic radicals, not substituted by cyclic structures attached to a nitrogen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1041—Ribosome/Polysome display, e.g. SPERT, ARM
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6867—Replicase-based amplification, e.g. using Q-beta replicase

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

내용 없음

Description

신규의 유전자 및 폴리펩티드의 무세포 합성 및 분리
[도면의 간단한 설명]
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (47)

  1. (a) RNA 폴리머라제 결합 시퀀스, 리보솜 결합 시퀀스, 및 번역 개시 시그널을 함유한 5'미번역 영역으로 이루어진, mRNA를 생성할 수 있는 시험관내 발현 유니트를 조립하고; (b) 한가지 또는 그이상의 세미-랜덤 뉴클레오티드 시퀀스를 그 발현 유니트에 부착하고; (c) 발현 유니트 및 세미-랜덤 뉴클레오티드와 관련된 시퀀스를 전사하거나 복제하여 RNA를 생성하며; (d) 그 RNA를 번역하여 폴리솜을 유지하는데 충분한 조건하에 폴리솜을 생성하며; (e) 그 폴리솜을 관심 물질에 결합하고; (f) 그 관심 물질에 결합하는 그 폴리솜을 분리하며; (g) 그 분리된 폴리솜을 분쇄하여 mRNA를 유리하며; (h) 그 mRNA를 회수하고; (i) 회수된 mRNA로 부터 cDNA를 조립하고; j) 그 cDNA를 발현시켜 신규의 폴리펩티드을 생성하는 것으로 이루어진 신규 폴리펩티드의 재조방법.
  2. 제1항에 있어서, mRNA를 회수하고 cDNA를 조립하는 단계에 이어서 cDNA를 폴리머라제 사슬 반응에 의하여 확대시키는 것이 특징인 방법.
  3. 제1항에 있어서, 상기 세이-랜덤 뉴클레오티드 시퀀스가 데옥시리보핵산으로 이루어진 것이 특징인 방법.
  4. 제1항에 있어서, 상기 세미-랜덤 뉴클레오디드 시퀀스카 리보핵산으로 이루어진 것이 특징인 방법.
  5. 제1항에 있어서, 상기 발현 유니트가 적어도 한개의 RNA-지시 RNA 폴리머라제 인식 시퀀스를 함유하는 것이 특징인 방법.
  6. 제5항에 있어서, 상기 RNA-지시 RNA 폴리머라제가 Q-베타 레플리카제인 것이 특징인 방법.
  7. 제1항에 있어서, 회수 단계에 이어서 mRNA를 확대시키는 것이 특징인 방법.
  8. 제7항에 있어서, 확대 단계가 복제 시퀀스를 RNA-의존 RNA 폴리머리제로서 합성시키는 것으로 이루어진 것이 특징인 방법.
  9. 제8항에 있어서, RNA-의존 RNA 폴리머라제가 Q-베타 레플리카제인 것이 특징인 방법.
  10. 제1항에 있어서, 분리 단계가 연속 회석 또는 병류 세척 단계에 의하여 관심 물질에 결합하지 않는 폴리솜을 제거하는 것으로 이루어진 것이 특징인 방법.
  11. 제1항에 있어서, 상기 폴리솜을 분리하는 단계에 이어서, 폴리솜이 관심 물질로부터 유리되도록 선택된 엄격한 조건에 상기 폴리솜을 노출시키는 것이 특징인 방법.
  12. 제11항에 있어서, 상기 폴리솜을 노출시키는 단계가 온도를 상승시키고, 염 농도를 저하시키고, 또는 그 폴리솜의 금속이온 농도는 상승시키는 것으로 이루어진 것이 특징인 방법.
  13. (a) RNA 폴리머라제 결합 시퀀스, 리보솜 결합 시퀀스, 및 번역 개시 시그널을 함유한 5'미번역 영역으로 이루어진, mRNA를 생성한 수 있는 시험관내 발현 유니트를 조립하고; (b) 한가지 모는 그이상의 세미-랜덤 뉴클레오티드 시퀀스를 그 발현 유니트에 부착하고; (c) 발현 유니트와 세미-랜덤 뉴클레오티드와 관련된 시퀀스를 전사시켜 RNA를 생성하며; (d) 그 RNA를 번역하여 생물학적 활성 폴리펩티드를 생성하며; (e) 그 생물학적 활성 폴리펩티드를 코드화하는 RNA를 세분하고; (f) 관심 유전자가 분리되도록 단계(c)-(e)에 제시된 바와같이 전사하고, 번역하며, 세분하며; (g) 그 분리된 유전자로 부터 cDNA를 조립한 다음; (h) 그 cDNA를 발현시켜 신규 폴리펩티드를 생성하는 것으로 이루어진 신규 폴리펩티드의 제조방법.
  14. (a) RNA 폴리머라제 결합 시퀀스, 리보솜 결합 시퀀스, 및 번역 개시 시그널을 함유한 5'미번역 영역으로 이루어진, mRNA을 생성할 수 있는 시힘관내 발현 유니트를 조립하고; (b) 한가지 또는 그이상의 세미-랜덤 뉴클레오티드 시퀀스를 발현 유니트에 부착하며; (c) 발현 유니트 및 세미-랜덤 뉴클레오티드 시퀀스와 관련된 시퀀스를 복제하여 RNA를 생성하며; (d) 그 RNA를 번역하여 생물학적 활성 폴리펩티드를 생성하고; (e) 그 생물학적 활성 폴리펩티드를 코드화하는 RNA를 세분하고, (f) 관심 유전자가 분리되도록 단계 (d)-(e)에 제시된 바와같이 번역 및 세분하며; (g) 그 분리된 유전자로 부터 cDNA를 조립한 다음; (h) 그 cDNA를 발현시켜 신규의 폴리펩티드를 생성하는 것으로 이루어진 신규 폴리펩티드의 제조방법.
  15. 제14항에 있어서, RNA를 세분하는 단계에 이어서, 생물학적 활성 폴리펩티드와 관련한 신규의 유전자 시퀀스를 폴리머라제 사슬 반응물 또는 RNA-지시 RNA 폴리머라제로서 확대하는 것이 특징인 방법.
  16. 제1, 13 또는 14항의 방법에 의하여 생성된 폴리펩티드.
  17. 제1, 13 또는 14항에 있어서, 상기 리보솜 결합 부위가 성숙핵, 원시핵, 또는 비루스 리보솜 결합 시퀀스로 이루어진 것이 특징인 방법.
  18. 제1, 13 또는 14항에 있어서, 상기 리보솜 결합 시퀀스가 척추동물의 교감 번역 개시 시퀀스, GCCGCCACCATGG, 또는 작용 관련 시퀀스로 이루어진 것이 특징인 방법.
  19. 제1, 13 또는 14항에 있어서, 발현 유니트가 추가로 선택된 아미노-말단 ID 펩티드를 코드화하는, 개시 코돈에 위치한 시퀀스로 이루어진 것이 특징인 방법.
  20. 제1, 13 또는 14항에 있어서, 상기 발현 유니트가 추가로 신규 유전자의 확대, 클로닝, 복제, 정제, 및 분리를 증가시키는 시퀀스중에서 선택된 선택 시퀀스의 3'영역으로 이루어진 것이 특징인 방법.
  21. 제20항에 있어서, 상기 3' 영역이 리보솜 전위를 방해하는데 적합한 회문형 시퀀스를 포함한 것이 특징인 방법.
  22. 제20항에 있어서, 상기 3' 영역이 C-말단 ID 시퀀스를 포힘한 것이 특징인 방법.
  23. 제22항에 있어서, 상기 C-말단 ID 시퀀스가 반복 시퀀스로 이루어진 것이 특징인 방법.
  24. 제22항에 있어서, 상기 C-말단 ID 시퀀스가 항체에 결합할 수 있는 펩티드를 코드화하는 것이 특징인 방법.
  25. 제1, 13 또는 14항에 있어서, 상기 발현 유니트가 추가로 생체내에서 신규 유전자를 발현시키는데 적합한 제한 부위로 이루어진 것이 특징인 방법.
  26. 제25항에 있어서, 상기 제한 부위의 적어도 한가지가 번역 출발점에 위치한 시퀀스 CCATGG로 이루어진 것이 특징인 방법.
  27. 제1, 13 또는 14항에 있어서, 상기 발현 유니트가 T7, T3, 또는 SP6폴리머라제를 위한 촉진인자 시퀀스를 포함한 것이 특징인 방법.
  28. 제1, 13 또는 14항에 있어서, 자연 발생 DNA 또는 cDNA를 기계적, 화학적, 또는 효소적으로 단편화함으로서 세미-랜덤 뉴클레오티드 시퀀스를 발생하는 것이 특징인 방법.
  29. 제1, 13 또는 14항에 있어서, 뉴클레오티드를 화학적으로 합성하므로서 세미-랜덤 뉴클레오티드를 발생시켜 유전자 시퀀스를 형성하는 것이 특징인 방법.
  30. 제29항에 있어서, 상기 뉴클레오티드를 화학적으로 합성하는 단계는 (1) 제1코돈 위치에서 실제 동일 몰량의 C, A 및 G 그리고 실제 동일 몰량의 T에서 단지 반만 사용하고; (2) 제2코돈 위치에서 실제 동일 몰량의 C, T, 및 G. 그리고 실제 동일 몰량의 A에서 단지 반만 사용한 다음; (3) 제3코돈 위치에서 실제 동일 몰량의 C와 G 또는 T와 G를 사용하는 단계로 이루어진 것이 특징인 방법.
  31. 제1, 13 또는 14항에 있어서, 부착 단계가 추가로 발현 유니트의 5'미번역 영역의 3'말단위에 바로 상기 뉴클레오티드를 중합시키는 것으로 이루어진 것이 특징인 방법.
  32. 제1 또는 13항에 있어서, 전사 단계가 디구아노신 트리포스페이트 또는 그의 동족체의 존재하에 상기 시퀀스를 전사하는 것으로 이루어진 것이 특징인 방법.
  33. 제1, 13 또는 14항에 있어서, 번역 단계가 디구아노신 트리포스페이트 또는 그의 동족체 및 구아닐일트란스퍼라제 존재하에 상기 시퀀스를 번역하는 것으로 이루어진 것이 특징인 방법.
  34. 제1, 13 또는 14항에 있어서, 번역 단계가 무의미-억제 tRNA 존재하에 수행되는 것이 특징인 방법.
  35. 제34항에 있어서, 무의미-억제 tRNA가 티로신-삽입, 무의미-억제 tRAN인 것이 특징인 방법.
  36. 제1, 13 또는 14항에 있어서, 상기 관심 물질이 표면 항원, 수용체 단백질, 톡신, 유기 중합체, 메타볼라이트, 단백질 분자의 활성부위, 호르몬, 항체, 및 오염물질중에서 선택되는 것이 특징인 방법.
  37. 제1, 13 또는 14항에 있어서, 상기 관심 물질이 항체의 가변/과도 가변 영역인 것이 특징인 방법.
  38. 제1, 13 또는 14항에 있어서, 상기 관심 물질이 수용체 단백질인 것이 특징인 방법.
  39. 제38항에 있어서, 상기 수용체 단백질이 성장인지 수용체 단백질인 것이 특징인 방법.
  40. 39항에 있어서, 상기 성장인자 수용체 단백질이 인슐린 및 상피 성장인자중에서 선택되는 것이 특징인 방법.
  41. 제1, 13 또는 14항에 있어서, 상기 관심 물질이 비루스 표면항원, 비루스 수용체 단백질 및 CD4 중에서 선택되는 것이 특징인 방법.
  42. 제1, 13 또는 14항에 있어서, cDNA를 발현시키는 단계가 그 cDNA의 뉴클레오티드 시퀀스를 기재로한 아미노산 시퀀스를 화학적으로 합성하는 것으로 이루어진 것이 특징인 방법.
  43. 제1, 13 또는 14항에 있어서, cDNA를 발현시키는 단계가 유전공학 미생물에서 합성을 위한 발현 벡터로 뉴클레오티드 시퀀스를 클로닝하는 것으로 이루어진 것이 특징인 방법.
  44. 제1, 13 또는 14항에 있어서, cDNA를 발현시키는 단계가 뉴클레오티드 시퀀스의 시험관내 전사 및/ 또는 번역으로 이루어진 것이 특징인 방법.
  45. 제1, 13 또는 14항에 있어서, cDNA를 발현시키는 단계가 cDNA에 의하여 코드화되는 것과 실제로 동일한 폴리폡티드를 코드화하는 뉴클레오티드 시퀀스를 합성하는 것으로 이루어지며, 뉴클레오티드 시퀀스에 의하여 코드화된 폴리폡티드는 관심물질에 결합하는 폴리솜의 결합영역과 실제 동일한 것이 특징인 방법.
  46. 제1, 13 또는 14항에 있어서, 상기 cDNA을 시퀀스 코드화 톡신, 항체, 효소, 생물활성 펩티드, 및 항체에 결합할 수 있는 펩티드중에서 선택된 다른 선택 뉴클레오티드 시퀀스에 결합하는 것이 특징인 방법.
  47. RNA 폴리머라제 결합 시퀀스, 리보솜 결합 시퀀스, 번역 개시 시그널을 함유한 5'미번역 영역으로 이루어진 시험관내 발현 유니트, 및 한가지 또는 그이상의 세미-랜덤 뉴클레오티드 시퀀스를 전사시져 mRNA 라이브러리를 생성하여; 부착된 폴리펩티드 사슬을 가진 폴리솜을 유지하는 조건하에 mRNA 라이브러리를 번역하고; 관심 물질에 폴리솜을 접촉하며 관심물질에 특이하게 결합하는 폴리솜으로 부터 mRNA를 분리하는 것으로 이루어진, 관심 폴리펩티드를 코드화하는 뉴클레오티드 시퀀스의 분리방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019920700769A 1989-10-05 1990-10-04 신규의 유전자 및 폴리펩티드의 무세포 합성 및 분리 KR0185192B1 (ko)

Priority Applications (2)

Application Number Priority Date Filing Date Title
KR1019980708672A KR100204359B1 (en) 1989-10-05 1998-10-28 Cell-free synthesis and isolation of novel gene and popyeptide
KR1019980708673A KR100204360B1 (en) 1989-10-05 1998-10-28 A method for identifying a polynucleotide molecule having a selected nucleic acid sequence from a library of random or semi-random polynucleotide molecules

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US41735789A 1989-10-05 1989-10-05
US417,357 1989-10-05
PCT/US1990/005682 WO1991005058A1 (en) 1989-10-05 1990-10-04 Cell-free synthesis and isolation of novel genes and polypeptides
US417357 1995-04-05

Publications (2)

Publication Number Publication Date
KR920703839A true KR920703839A (ko) 1992-12-18
KR0185192B1 KR0185192B1 (ko) 1999-04-01

Family

ID=23653670

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1019920700769A KR0185192B1 (ko) 1989-10-05 1990-10-04 신규의 유전자 및 폴리펩티드의 무세포 합성 및 분리
KR1019980708673A KR100204360B1 (en) 1989-10-05 1998-10-28 A method for identifying a polynucleotide molecule having a selected nucleic acid sequence from a library of random or semi-random polynucleotide molecules
KR1019980708672A KR100204359B1 (en) 1989-10-05 1998-10-28 Cell-free synthesis and isolation of novel gene and popyeptide

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1019980708673A KR100204360B1 (en) 1989-10-05 1998-10-28 A method for identifying a polynucleotide molecule having a selected nucleic acid sequence from a library of random or semi-random polynucleotide molecules
KR1019980708672A KR100204359B1 (en) 1989-10-05 1998-10-28 Cell-free synthesis and isolation of novel gene and popyeptide

Country Status (11)

Country Link
US (2) US5658754A (ko)
EP (1) EP0494955B1 (ko)
JP (2) JP3127158B2 (ko)
KR (3) KR0185192B1 (ko)
AT (1) ATE168416T1 (ko)
AU (1) AU638762B2 (ko)
CA (1) CA2067194C (ko)
DE (1) DE69032483T2 (ko)
DK (1) DK0494955T3 (ko)
ES (1) ES2118066T3 (ko)
WO (1) WO1991005058A1 (ko)

Families Citing this family (344)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747334A (en) * 1990-02-15 1998-05-05 The University Of North Carolina At Chapel Hill Random peptide library
US5498538A (en) * 1990-02-15 1996-03-12 The University Of North Carolina At Chapel Hill Totally synthetic affinity reagents
US5962219A (en) * 1990-06-11 1999-10-05 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-selex
US5843701A (en) * 1990-08-02 1998-12-01 Nexstar Pharmaceticals, Inc. Systematic polypeptide evolution by reverse translation
US5795747A (en) * 1991-04-16 1998-08-18 Evotec Biosystems Gmbh Process for manufacturing new biopolymers
DE4112440C1 (ko) * 1991-04-16 1992-10-22 Diagen Institut Fuer Molekularbiologische Diagnostik Gmbh, 4000 Duesseldorf, De
WO1993003172A1 (en) * 1991-08-01 1993-02-18 University Research Corporation Systematic polypeptide evolution by reverse translation
US5783384A (en) * 1992-01-13 1998-07-21 President And Fellows Of Harvard College Selection of binding-molecules
US5728802A (en) * 1992-05-06 1998-03-17 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelium leukocyte adhesion molecule 1 (ELAM-1)
US5643873A (en) * 1992-05-06 1997-07-01 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelial leukocyte adhesion molecule 1
US5648458A (en) * 1992-05-06 1997-07-15 Affymax Technologies N.V. Peptides and compounds that bind to ELAM-1
WO1994005812A1 (en) * 1992-09-02 1994-03-17 The Scripps Research Institute Coupled isothermal polynucleotide amplification and translation system
WO1995011922A1 (en) * 1993-10-29 1995-05-04 Affymax Technologies N.V. In vitro peptide and antibody display libraries
US5922545A (en) * 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
US5525734A (en) * 1994-06-22 1996-06-11 Affymax Technologies N.V. Methods for synthesizing diverse collections of pyrrolidine compounds
US5525735A (en) * 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
AU3719395A (en) * 1994-09-21 1996-04-09 Cytogen Corporation Antigen binding peptides (abtides) from peptide libraries
US5885577A (en) * 1994-09-21 1999-03-23 Cytogen Corporation Antigen binding peptides (abtides) from peptide libraries
EP0800526B1 (en) * 1994-12-30 2003-03-26 Chiron Corporation Method for the controlled synthesis of polynucleotide mixtures which encode desired mixtures of peptides
US6341256B1 (en) * 1995-03-31 2002-01-22 Curagen Corporation Consensus configurational bias Monte Carlo method and system for pharmacophore structure determination
US20010053523A1 (en) * 1995-06-02 2001-12-20 M&E Biotech A/S. Method for identification of biologically active peptides and nucleic acids
US6537776B1 (en) 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
JP2000511050A (ja) * 1996-05-31 2000-08-29 メディジーン・アクチェンゲゼルシャフト 機能性分子表面の生成、スクリーニング、および展開のための新規の合成タンパク質の構造の鋳型
US6875620B1 (en) * 1996-10-31 2005-04-05 Agilent Technologies, Inc. Tiling process for constructing a chemical array
PT971946E (pt) 1997-01-21 2006-11-30 Gen Hospital Corp Selecção de proteínas utilizando fusões arn-proteína
US8207093B2 (en) 1997-01-21 2012-06-26 The General Hospital Corporation Selection of proteins using RNA-protein fusions
US6261804B1 (en) 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
GB2338237B (en) * 1997-02-18 2001-02-28 Actinova Ltd In vitro peptide or protein expression library
GB9703369D0 (en) * 1997-02-18 1997-04-09 Lindqvist Bjorn H Process
CA2289691C (en) 1997-04-23 2008-01-15 Andreas Pluckthun Methods for identifying nucleic acid molecules encoding (poly)peptides that interact with target molecules
EP1801214B1 (en) 1997-07-07 2010-11-10 Medical Research Council In vitro sorting method
US6066460A (en) * 1997-07-24 2000-05-23 President And Fellows Of Harvard College Method for cloning secreted proteins
EP1003853B1 (en) * 1997-09-03 2005-11-30 Biovation Limited Methods for protein screening
US6927025B1 (en) 1997-09-03 2005-08-09 Biovation Limited Methods for protein screening
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
DE1068357T1 (de) 1998-03-30 2001-07-19 Northwest Biotherapeutics Inc Therapeutische und diagnostische anwendungen welche auf der rolle von cxcr-4 in der tumorgenese basieren
WO1999051773A1 (en) * 1998-04-03 1999-10-14 Phylos, Inc. Addressable protein arrays
US6440695B1 (en) * 1998-04-17 2002-08-27 Whitehead Institute For Biomedical Research Method for producing diverse libraries of encoded polypeptides
US6562622B1 (en) * 1998-05-08 2003-05-13 Diatech Pty, Ltd Continuous in vitro evolution
US20030170820A1 (en) * 1998-05-08 2003-09-11 Gregory Coia Continuous in- vitro evolution
GB9810756D0 (en) 1998-05-19 1998-07-15 Angeletti P Ist Richerche Bio Mimotopes of hypervariable region 1 of the e2 glycoprotein of hcv and uses thereof
EP1092046A4 (en) * 1998-07-02 2003-02-19 Invitro Diagnostics Inc METHODS, COMPOSITIONS AND DEVICE FOR MANUFACTURING NUCLEIC ACIDS HAVING SELECTIVE AFFINITY FOR A TARGET MOLECULE
US20100130368A1 (en) * 1998-07-30 2010-05-27 Shankar Balasubramanian Method and system for sequencing polynucleotides
US20040106110A1 (en) * 1998-07-30 2004-06-03 Solexa, Ltd. Preparation of polynucleotide arrays
US20030022207A1 (en) * 1998-10-16 2003-01-30 Solexa, Ltd. Arrayed polynucleotides and their use in genome analysis
US6787308B2 (en) * 1998-07-30 2004-09-07 Solexa Ltd. Arrayed biomolecules and their use in sequencing
US20040002101A1 (en) * 1998-08-12 2004-01-01 Proteus S.A. Method and kit for discovering nucleic acids that encode desired functions
EP1105516A4 (en) * 1998-08-17 2002-01-09 Phylos Inc METHODS FOR PRODUCING PRIVATE NUCLEIC ACIDS FROM 3 'NON-TRANSLATED REGIONS AND FOR OPTIMIZING THE FORMATION OF A CELL-PROTEIN RNA FUSION
AU757955B2 (en) 1998-08-17 2003-03-13 Bristol-Myers Squibb Company Identification of compound-protein interactions using libraries of protein-nucleic acid fusion molecules
US20060088846A1 (en) 1998-08-28 2006-04-27 Michele Pagano Methods to identify compounds useful for the treatment of proliferative and differentiative disorders
ES2280131T3 (es) 1998-12-02 2007-09-01 Adnexus Therapeutics, Inc. Fusiones de adn-proteina y utilizaciones de las mismas.
US7883704B2 (en) * 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
TR200603997T1 (tr) 1999-03-25 2010-01-21 Abbott Gmbh & Co. Kg Beşeri IL-12'yi bağlayan beşeri antikorlar ve bunları üretmek için yöntemler.
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
WO2000069898A2 (en) 1999-05-14 2000-11-23 Arbor Vita Corporation Molecular interactions in allergy cells
JP2003500081A (ja) 1999-06-01 2003-01-07 フィロス インク． ５’核酸−タンパク質結合体の生成法
US20030091999A1 (en) * 1999-10-01 2003-05-15 Zhongping Yu Compositions and methods for identifying polypeptides and nucleic acid molecules
US7022479B2 (en) 2000-01-24 2006-04-04 Compound Therapeutics, Inc. Sensitive, multiplexed diagnostic assays for protein analysis
US6489116B2 (en) 2000-01-24 2002-12-03 Phylos, Inc. Sensitive, multiplexed diagnostic assays for protein analysis
ATE311444T1 (de) * 2000-03-31 2005-12-15 Cambridge Antibody Tech Verbesserungen in bezug auf ribosom-komplexe als selektionspartikel
JP2003530838A (ja) 2000-04-12 2003-10-21 ヒューマン ゲノム サイエンシズ インコーポレイテッド アルブミン融合タンパク質
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
AU2001285066B2 (en) 2000-08-18 2006-06-29 Human Genome Sciences, Inc. Binding polypeptides for B lymphocyte stimulator protein (BLYS)
AU2002218166A1 (en) 2000-09-08 2002-03-22 Universitat Zurich Collections of repeat proteins comprising repeat modules
JP4723713B2 (ja) * 2000-09-25 2011-07-13 トヨタ自動車株式会社 ｍＲＮＡの潜在的翻訳制御因子のスクリーニング方法
US20040091509A1 (en) * 2000-12-14 2004-05-13 Avon Products, Inc. Skin care composition that mediates cell to cell communication
KR100401296B1 (ko) * 2000-12-27 2003-10-11 드림바이오젠 주식회사 수식물질에 의해 수식된 단백질 변이체 및 이것의 제조방법
JP4061043B2 (ja) 2000-12-28 2008-03-12 株式会社ポストゲノム研究所 ｉｎｖｉｔｒｏ転写／翻訳系によるペプチド等の製造方法
EP1423400B2 (en) 2001-03-19 2013-05-22 President and Fellows of Harvard College Evolving new molecular function
EP1249499A1 (de) * 2001-04-10 2002-10-16 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren und Vorrichtung zur Bestimmung und Selektion von Molekül-Molekül-Wechselwirkungen
AU2002257142B2 (en) 2001-04-13 2008-09-04 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7727713B2 (en) 2001-06-20 2010-06-01 Nuevolution A/S Templated molecules and methods for using such molecules
EP1402024B1 (en) 2001-06-20 2007-08-22 Nuevolution A/S Templated molecules and methods for using such molecules
GB0115841D0 (en) 2001-06-28 2001-08-22 Medical Res Council Ligand
DK1440083T3 (da) 2001-10-25 2013-03-25 Medical Res Council Molekyler
GB0126887D0 (en) * 2001-11-08 2002-01-02 Univ London Method for producing and identifying soluble protein domains
GB0127564D0 (en) 2001-11-16 2002-01-09 Medical Res Council Emulsion compositions
EP1461462A4 (en) * 2001-12-19 2006-01-11 Roche Diagnostics Gmbh HIGH PERFORMANCE POLYPEPTIDE SCREEN BASED ON PCR (POLYMERASE CHAIN REACTION)
US20040052928A1 (en) * 2002-09-06 2004-03-18 Ehud Gazit Peptides and methods using same for diagnosing and treating amyloid-associated diseases
US7781396B2 (en) * 2002-01-31 2010-08-24 Tel Aviv University Future Technology Development L.P. Peptides directed for diagnosis and treatment of amyloid-associated disease
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
EP2221377B2 (en) 2002-02-01 2017-05-17 Life Technologies Corporation Oligonucleotide compositions with enhanced efficiency
WO2003064621A2 (en) 2002-02-01 2003-08-07 Ambion, Inc. HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
AU2003217716A1 (en) * 2002-02-25 2003-09-09 Cabot Corporation Custom ligand design for biomolecular filtration and purification for bioseperation
EP1487978B1 (en) 2002-03-15 2008-11-19 Nuevolution A/S An improved method for synthesising templated molecules
MXPA04009778A (es) 2002-04-08 2004-12-13 Pionner Hi Bred International Exsercion de fibra sedosa mejorada bajo estres.
JP4744140B2 (ja) 2002-05-10 2011-08-10 ザ・ヘンリー・エム・ジャクソン・ファンデイション・フォー・ジ・アドヴァンスメント・オヴ・ミリタリー・メディシン、インコーポレイテッド アンドロゲン調節性ｐｍｅｐａ１遺伝子および癌細胞増殖を抑制するための同遺伝子の使用方法
AU2003243541A1 (en) * 2002-06-12 2003-12-31 Ambion, Inc. Methods and compositions relating to labeled rna molecules that reduce gene expression
US20100075423A1 (en) * 2002-06-12 2010-03-25 Life Technologies Corporation Methods and compositions relating to polypeptides with rnase iii domains that mediate rna interference
US20040248094A1 (en) * 2002-06-12 2004-12-09 Ford Lance P. Methods and compositions relating to labeled RNA molecules that reduce gene expression
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
US10730906B2 (en) 2002-08-01 2020-08-04 Nuevolutions A/S Multi-step synthesis of templated molecules
JP4657919B2 (ja) 2002-08-19 2011-03-23 プレジデント アンド フェローズ オブ ハーバード カレッジ 進化する新しい分子機能
US7842476B2 (en) 2002-09-06 2010-11-30 Isogenica Limited In vitro peptide expression library
JP4694840B2 (ja) 2002-09-09 2011-06-08 アルボー ビータ コーポレーション 子宮頸部癌を検査する方法
WO2004028682A2 (en) 2002-09-27 2004-04-08 Carlsberg A/S Spatially encoded polymer matrix
CN106337046B (zh) 2002-10-30 2021-03-23 纽韦卢森公司 合成双功能复合物的方法
JP2006505271A (ja) * 2002-11-04 2006-02-16 アイコジェネックス コーポレイション 膜結合前駆タンパク質の構造およびプロセシングを調節する物質の同定のための方法
EP1563066A4 (en) * 2002-11-04 2006-06-07 Bioarctic Neuroscience Ab METHODS OF IDENTIFYING AGENTS MODULATING THE STRUCTURE AND TREATMENT OF THE BETA-AMYLOID PRECURSOR PROTEIN
US7491699B2 (en) 2002-12-09 2009-02-17 Ramot At Tel Aviv University Ltd. Peptide nanostructures and methods of generating and using the same
WO2004056994A2 (en) 2002-12-19 2004-07-08 Nuevolution A/S Quasirandom structure and function guided synthesis methods
ATE426575T1 (de) 2003-01-07 2009-04-15 Univ Ramot Peptidenanostrukturen die fremdmaterial enthalten,und verfahren zur herstellung derselben
EP2159285B1 (en) 2003-01-29 2012-09-26 454 Life Sciences Corporation Methods of amplifying and sequencing nucleic acids
EP1597395A2 (en) 2003-02-21 2005-11-23 Nuevolution A/S Method for producing second-generation library
US20100022414A1 (en) 2008-07-18 2010-01-28 Raindance Technologies, Inc. Droplet Libraries
EP2236606B1 (en) 2003-03-20 2013-11-06 Nuevolution A/S Ligational encoding of small molecules
GB0307428D0 (en) 2003-03-31 2003-05-07 Medical Res Council Compartmentalised combinatorial chemistry
GB0307403D0 (en) 2003-03-31 2003-05-07 Medical Res Council Selection by compartmentalised screening
US20060078893A1 (en) 2004-10-12 2006-04-13 Medical Research Council Compartmentalised combinatorial chemistry by microfluidic control
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
JP5183063B2 (ja) 2003-07-05 2013-04-17 ザ ジョンズ ホプキンス ユニバーシティ 遺伝的変異の検出および列挙のための方法ならびに組成物
US7585815B2 (en) * 2003-07-24 2009-09-08 Lawrence Livermore National Security, Llc High throughput protein production screening
WO2005023993A2 (en) 2003-09-09 2005-03-17 Integrigen, Inc. Methods and compositions for generation of germline human antibody genes
DK1670939T3 (da) 2003-09-18 2010-03-01 Nuevolution As Fremgangsmåde til opnåelse af strukturel information om et kodet molekyle og fremgangsmåde til udvælgelse af forbindelser
CA2540407A1 (en) * 2003-09-25 2005-03-31 Tel Aviv University Future Technology Development L.P. Compositions and methods using same for treating amyloid-associated diseases
US7625707B2 (en) * 2003-10-02 2009-12-01 Ramot At Tel Aviv University Ltd. Antibacterial agents and methods of identifying and utilizing same
WO2005058479A2 (en) 2003-12-17 2005-06-30 Praecis Pharmaceuticals, Inc. Methods for synthesis of encoded libraries
US7972994B2 (en) 2003-12-17 2011-07-05 Glaxosmithkline Llc Methods for synthesis of encoded libraries
US7858322B2 (en) 2003-12-23 2010-12-28 Nono, Inc. Method of determining inhibition of binding to TRPM7 protein
DK1730277T3 (da) 2004-03-22 2010-03-01 Nuevolution As Kodning ved ligering under anvendelse af byggebloksoligonukleotider
US20050221339A1 (en) 2004-03-31 2005-10-06 Medical Research Council Harvard University Compartmentalised screening by microfluidic control
ES2770067T3 (es) 2004-05-11 2020-06-30 Ncardia Ag Descubrimiento de fármacos basado en células diferenciadas in vitro
US20090156471A1 (en) * 2004-07-15 2009-06-18 Ramot At Tel Aviv University Ltd. Use of anti-amyloid agents for treating and typing pathogen infections
EP1781310B1 (en) * 2004-08-02 2015-10-14 Ramot at Tel Aviv University Ltd. Articles of peptide nanostructures and method of forming the same
ATE539745T1 (de) 2004-08-19 2012-01-15 Univ Tel Aviv Future Tech Dev Zusammensetzungen zur behandlung von amyloid- assoziierten erkrankungen
US7300773B2 (en) * 2004-08-27 2007-11-27 Wyeth Research Ireland Limited Production of TNFR-Ig
US7335491B2 (en) 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
US7786086B2 (en) * 2004-09-08 2010-08-31 Ramot At Tel-Aviv University Ltd. Peptide nanostructures containing end-capping modified peptides and methods of generating and using the same
CN101724071A (zh) 2004-10-08 2010-06-09 杜门蒂斯有限公司 抗肿瘤坏死因子受体1的单域抗体及其使用方法
US7968287B2 (en) 2004-10-08 2011-06-28 Medical Research Council Harvard University In vitro evolution in microfluidic systems
KR100730875B1 (ko) 2004-12-07 2007-06-20 가부시키가이샤 시마즈세이사쿠쇼 번역반응 촉진 ｄｎａ 단편 및 그것을 사용한 무세포계단백질 합성방법
US20060142228A1 (en) * 2004-12-23 2006-06-29 Ambion, Inc. Methods and compositions concerning siRNA's as mediators of RNA interference
JP2008532559A (ja) 2005-03-19 2008-08-21 メディカル リサーチ カウンシル ウイルス感染の治療及び予防又は治療及び予防の改善
PE20061324A1 (es) 2005-04-29 2007-01-15 Centocor Inc Anticuerpos anti-il-6, composiciones, metodos y usos
WO2006123445A1 (ja) * 2005-05-18 2006-11-23 Kyoto University タンパク質の表示方法
EP1896073B1 (en) 2005-06-30 2013-03-06 Janssen Biotech, Inc. Anti-il-23 antibodies, compositions, methods and uses
CA2617539A1 (en) 2005-07-01 2007-01-11 Washington University In St. Louis Phosphospecific chemokine receptor antibodies
WO2007011722A2 (en) 2005-07-15 2007-01-25 President And Fellows Of Harvard College Reaction discovery system
US20070111237A1 (en) * 2005-09-14 2007-05-17 Maurizio Zanetti Process for identifying antigenized antibodies using ribosome cell free expression system
EP1973928A2 (en) * 2005-10-11 2008-10-01 Ramot at Tel-Aviv University Ltd. Self-assembled fmoc-ff hydrogels
US7989395B2 (en) 2005-10-28 2011-08-02 Glaxosmithkline Llc Methods for identifying compounds of interest using encoded libraries
US7879212B2 (en) * 2005-11-03 2011-02-01 Ramot At Tel-Aviv University Ltd. Peptide nanostructure-coated electrodes
DK2336315T3 (da) 2005-12-01 2017-11-06 Nuevolution As Fremgangsmåde til enzymatisk kodning ved effektiv syntese af store biblioteker
ES2517420T3 (es) 2005-12-29 2014-11-03 Janssen Biotech, Inc. Anticuerpos anti-IL-23 humanos, composiciones, procedimientos y usos
EP3913375A1 (en) 2006-01-11 2021-11-24 Bio-Rad Laboratories, Inc. Microfluidic devices and methods of use in the formation and control of nanoreactors
WO2007111661A2 (en) 2006-03-20 2007-10-04 Xoma Technology Ltd. Human antibodies specific for gastrin materials and methods
US7749957B2 (en) 2006-04-06 2010-07-06 E.I. Du Pont De Nemours And Company Clay-binding peptides and methods of use
EP2481815B1 (en) 2006-05-11 2016-01-27 Raindance Technologies, Inc. Microfluidic devices
US9562837B2 (en) 2006-05-11 2017-02-07 Raindance Technologies, Inc. Systems for handling microfludic droplets
WO2008005290A2 (en) 2006-06-29 2008-01-10 The Trustees Of Columbia University In The City Of New York Methods for testing anti-thrombotic agents
US8685925B2 (en) 2006-07-11 2014-04-01 Nono Inc. Method and compositions for treating stroke with fever
WO2008021123A1 (en) 2006-08-07 2008-02-21 President And Fellows Of Harvard College Fluorocarbon emulsion stabilizing surfactants
US9580515B2 (en) 2006-08-21 2017-02-28 Zensun (Shanghai) Science & Technology, Co., Ltd. Neukinase, a downstream protein of neuregulin
US20110294782A1 (en) 2006-11-10 2011-12-01 Massachusetts Institute Of Technology Small molecule pak inhibitors
US7695718B2 (en) 2006-12-20 2010-04-13 Xoma Technology Ltd. Methods for the treatment of IL-1β related diseases
KR20090100461A (ko) 2007-01-16 2009-09-23 아보트 러보러터리즈 건선의 치료방법
WO2008097559A2 (en) 2007-02-06 2008-08-14 Brandeis University Manipulation of fluids and reactions in microfluidic systems
CN101679507A (zh) 2007-03-29 2010-03-24 艾博特公司 结晶抗人类il-12抗体
WO2008130623A1 (en) 2007-04-19 2008-10-30 Brandeis University Manipulation of fluids, fluid components and reactions in microfluidic systems
EP2182943B1 (en) 2007-07-23 2016-10-26 Janssen Biotech, Inc. Methods and compositions for treating fibrosis related disorders using il-17 antagonists
US7678883B2 (en) 2007-07-25 2010-03-16 E.I. Du Pont De Nemours And Company Solubility tags for the expression and purification of bioactive peptides
US7829311B2 (en) 2007-07-25 2010-11-09 E.I. Du Pont De Nemours And Company Ketosteroid isomerase inclusion body tag engineered to be acid-resistant by replacing aspartates with glutamate
US7951559B2 (en) * 2007-07-25 2011-05-31 E.I. Du Pont De Nemours And Company Recombinant peptide production using a cross-linkable solubility tag
US7794963B2 (en) 2007-11-02 2010-09-14 E.I. Du Pont De Nemours And Company Use of tetracysteine tags in fluorescence-activated cell sorting analysis of prokaryotic cells producing peptides or proteins
BRPI0819743A2 (pt) 2007-11-20 2014-10-07 Pioneer Hi Bred Int Ácido nucléico isolado, cassete de expressão, célula hospedeira, planta transgênica, semente transgênica, método para modular a resposta de etileno em uma planta, proteína isolada
CA2710252C (en) 2007-12-20 2017-03-28 Xoma Technology Ltd. Methods for the treatment of gout
TW201513883A (zh) 2008-03-18 2015-04-16 Abbvie Inc 治療牛皮癬的方法
GB0806562D0 (en) 2008-04-10 2008-05-14 Fermentas Uab Production of nucleic acid
JP2010043063A (ja) 2008-05-09 2010-02-25 Agency For Science Technology & Research 川崎病の診断及び治療
JP5924937B2 (ja) 2008-07-25 2016-05-25 エックス−ボディ インコーポレイテッド タンパク質スクリーニング法
US8563697B2 (en) 2008-08-14 2013-10-22 Cephalon Australia Pty. Ltd. Anti-IL-12/IL-23 antibodies
US20100113304A1 (en) * 2008-09-26 2010-05-06 Wyeth Compatible display vector systems
US8313942B2 (en) * 2008-09-26 2012-11-20 Wyeth Llc Compatible display vector systems
US8278419B2 (en) 2008-10-31 2012-10-02 Centocor Ortho Biotech Inc. Fibronectin type III domain based scaffold compositions, methods and uses
US9403904B2 (en) 2008-11-07 2016-08-02 Fabrus, Inc. Anti-DLL4 antibodies and uses thereof
CN104398471A (zh) * 2008-11-28 2015-03-11 Abbvie公司 稳定的抗体组合物和用于稳定其的方法
US20100158837A1 (en) 2008-12-18 2010-06-24 E. I. Du Pont De Nemours And Company Iron oxide-binding peptides
US8287845B2 (en) * 2008-12-18 2012-10-16 E I Du Pont De Nemours And Company Hair-binding peptides
US20100158822A1 (en) 2008-12-18 2010-06-24 E .I. Du Pont De Nemours And Company Peptides that bind to silica-coated particles
US20100158846A1 (en) * 2008-12-18 2010-06-24 E. I. Du Pont De Nemours And Company Hair-binding peptides
JP2012513464A (ja) 2008-12-23 2012-06-14 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク ホスホジエステラーゼ阻害剤及びその使用
WO2010074783A1 (en) 2008-12-23 2010-07-01 The Trustees Of Columbia University In The City Of New York Phosphodiesterase inhibitors and uses thereof
DK2396011T3 (en) 2009-02-12 2016-04-25 Janssen Biotech Inc Fibronectin TYPE III DOMAIN-BASED SCAFFOLD COMPOSITIONS, METHODS AND USES
US8716553B2 (en) 2009-03-02 2014-05-06 Pioneer Hi Bred International Inc NAC transcriptional activators involved in abiotic stress tolerance
US8528589B2 (en) 2009-03-23 2013-09-10 Raindance Technologies, Inc. Manipulation of microfluidic droplets
WO2010114638A1 (en) 2009-03-30 2010-10-07 E. I. Du Pont De Nemours And Company Peptide-based tooth whitening reagents
BRPI1014677A2 (pt) 2009-03-30 2016-04-12 Du Pont sistemas baseados em peptídeos para distribuição de agentes cosméticos
US20110035843A1 (en) 2009-08-05 2011-02-10 Pioneer Hi-Bred International, Inc. Novel eto1 genes and use of same for reduced ethylene and improved stress tolerance in plants
KR101161622B1 (ko) * 2009-08-31 2012-07-04 헬릭스 주식회사 번역 효율 증진용 ｄｎａ 단편 및 이를 포함하는 재조합 벡터
RU2012114854A (ru) * 2009-09-14 2013-10-27 Эбботт Лэборетриз Способы лечения псориаза
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
CA2772945A1 (en) 2009-09-25 2011-03-31 Xoma Technology Ltd. Screening methods
WO2011042564A1 (en) 2009-10-09 2011-04-14 Universite De Strasbourg Labelled silica-based nanomaterial with enhanced properties and uses thereof
JP2013508287A (ja) 2009-10-14 2013-03-07 ヤンセン バイオテツク，インコーポレーテツド 抗体を親和性成熟する方法
US20110165648A1 (en) 2009-11-04 2011-07-07 Menno Van Lookeren Campagne Co-crystal structure of factor D and anti-factor D antibody
IL201999A (en) 2009-11-08 2017-10-31 Medical Res & Development Fund For Health Services Bnai Zion Medical Center The State Of Israel A knockout mouse of the 1 – mo gene, a gene associated with morbidly extreme obesity
US10640457B2 (en) 2009-12-10 2020-05-05 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase activators and uses thereof
JP6093180B2 (ja) 2009-12-10 2017-03-08 トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク ヒストンアセチルトランスフェラーゼ活性化剤及びその使用
WO2011079176A2 (en) 2009-12-23 2011-06-30 Raindance Technologies, Inc. Microfluidic systems and methods for reducing the exchange of molecules between droplets
MX341687B (es) 2010-02-10 2016-08-30 Immunogen Inc "anticuerpos cd20 y su utilización".
US10351905B2 (en) 2010-02-12 2019-07-16 Bio-Rad Laboratories, Inc. Digital analyte analysis
US9399797B2 (en) 2010-02-12 2016-07-26 Raindance Technologies, Inc. Digital analyte analysis
US9366632B2 (en) 2010-02-12 2016-06-14 Raindance Technologies, Inc. Digital analyte analysis
JP5934657B2 (ja) 2010-02-12 2016-06-15 レインダンス テクノロジーズ， インコーポレイテッド デジタル検体分析
EP2546342A4 (en) 2010-03-11 2013-12-04 Riken METHOD FOR SELECTION OF A POLYPEPTIDE SEQUENCE, METAL OXIDE OR SILICON WITH A BONDING SPEPTIDE AND USE THEREOF
EP3540059A1 (en) 2010-04-16 2019-09-18 Nuevolution A/S Bi-functional complexes and methods for making and using such complexes
BR112012027863B1 (pt) 2010-04-30 2023-03-07 Janssen Biotech, Inc Polipeptídeos, arcabouços de proteína, bibliotecas e métodos de construção das mesmas, método para gerar uma ligação de arcabouço de proteína a um alvo específico com uma afinidade de ligação predefinida, moléculas de ácido nucleico isolada, vetores, células hospedeiras, composições, dispositivos médicos, e artigos de fabricação
WO2012022734A2 (en) 2010-08-16 2012-02-23 Medimmune Limited Anti-icam-1 antibodies and methods of use
CA2807607A1 (en) 2010-08-20 2012-02-23 Wyeth Llc Cell culture of growth factor-free adapted cells
EP2614073B1 (en) 2010-09-07 2018-03-14 Technische Universität München Recombinant bacterial lipocalin blc and uses thereof
EP2622103B2 (en) 2010-09-30 2022-11-16 Bio-Rad Laboratories, Inc. Sandwich assays in droplets
US9198911B2 (en) 2010-11-02 2015-12-01 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
WO2012061537A2 (en) 2010-11-02 2012-05-10 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
JP6616057B2 (ja) 2010-12-22 2019-12-04 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク ヒストンアセチル基転移酵素モジュレーターおよびその使用
DE102010056289A1 (de) 2010-12-24 2012-06-28 Geneart Ag Verfahren zur Herstellung von Leseraster-korrekten Fragment-Bibliotheken
EP3859011A1 (en) 2011-02-11 2021-08-04 Bio-Rad Laboratories, Inc. Methods for forming mixed droplets
WO2012112804A1 (en) 2011-02-18 2012-08-23 Raindance Technoligies, Inc. Compositions and methods for molecular labeling
JP5948673B2 (ja) 2011-03-10 2016-07-06 ジーンフロンティア株式会社 リポ多糖混入量を低減した蛋白質合成用組成物、該組成物を用いた蛋白質製造方法
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US20120301904A1 (en) 2011-04-26 2012-11-29 Prosetta Antiviral, Inc Multiprotein assemblies
JP6057297B2 (ja) 2011-05-23 2017-01-11 国立研究開発法人理化学研究所 核酸構築物、核酸−蛋白質複合体、及びその利用
EP3709018A1 (en) 2011-06-02 2020-09-16 Bio-Rad Laboratories, Inc. Microfluidic apparatus for identifying components of a chemical reaction
US8841071B2 (en) 2011-06-02 2014-09-23 Raindance Technologies, Inc. Sample multiplexing
ES2894398T3 (es) 2011-06-03 2022-02-14 Xoma Technology Ltd Anticuerpos específicos para TGF-beta
US8658430B2 (en) 2011-07-20 2014-02-25 Raindance Technologies, Inc. Manipulating droplet size
WO2013033657A2 (en) 2011-09-02 2013-03-07 The Trustees Of Columbia University In The City Of New York CaMKII, IP3R, CALCINEURIN, P38 AND MK2/3 INHIBITORS TO TREAT METABOLIC DISTURBANCES OF OBESITY
HUE036177T2 (hu) 2011-09-19 2018-06-28 Axon Neuroscience Se TAU-mediált patológia protein alapú terápiája és diagnózisa Alzheimer-betegségben
KR102142385B1 (ko) 2011-09-27 2020-08-10 얀센 바이오테크 인코포레이티드 대체 결합 표면을 가진 피브로넥틴 유형 iii 반복체 기반의 단백질 스캐폴드
SG11201401220SA (en) 2011-10-21 2014-07-30 Pfizer Addition of iron to improve cell culture
CA2853449A1 (en) 2011-10-25 2013-05-02 Pioneer Hi-Bred International, Inc. Methods to alter plant cell wall composition for improved biofuel production and silage digestibility
WO2013096516A1 (en) 2011-12-19 2013-06-27 Xoma Technology Ltd. Methods for treating acne
PT2830662T (pt) 2012-03-29 2018-11-29 Univ Columbia Métodos para tratamento de distúrbios de perda de pelo
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
AU2013243946A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of membrane proteins
EP2657334B1 (en) 2012-04-26 2016-07-06 GeneFrontier Corporation Efficient method for displaying protein multimer
WO2013172954A1 (en) 2012-05-17 2013-11-21 Ra Pharmaceuticals, Inc Peptide and peptidomimetic inhibitors
GB201214029D0 (en) * 2012-08-07 2012-09-19 Queen Mary & Westfield College method
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
DK3447069T3 (da) 2012-11-21 2020-11-16 Janssen Biotech Inc Bispecifikke egfr/c-met-antistoffer
WO2014152507A2 (en) 2013-03-15 2014-09-25 Pioneer Hi-Bred International, Inc. Modulation of acc deaminase expression
WO2014152031A1 (en) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Ribonucleic acid purification
US10590161B2 (en) 2013-03-15 2020-03-17 Modernatx, Inc. Ion exchange purification of mRNA
WO2014152027A1 (en) * 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Manufacturing methods for production of rna transcripts
EP2971165A4 (en) 2013-03-15 2016-11-23 Moderna Therapeutics Inc DISSOLUTION OF DNA FRAGMENTS IN MRNA MANUFACTURING METHODS
PL3019619T3 (pl) 2013-07-11 2022-01-10 Modernatx, Inc. Kompozycje zawierające syntetyczne polinkleotydy kodujące białka powiązane z crispr i syntetyczne sgrna oraz sposoby ich stosowania
WO2015051169A2 (en) 2013-10-02 2015-04-09 Moderna Therapeutics, Inc. Polynucleotide molecules and uses thereof
US11901041B2 (en) 2013-10-04 2024-02-13 Bio-Rad Laboratories, Inc. Digital analysis of nucleic acid modification
AU2014334627B2 (en) 2013-10-14 2019-07-25 Janssen Biotech, Inc. Cysteine engineered fibronectin type III domain binding molecules
US9309314B2 (en) 2013-12-03 2016-04-12 Agency For Science, Technology And Research (A*Star) Polypeptides, nucleic acids and uses thereof
US9944977B2 (en) 2013-12-12 2018-04-17 Raindance Technologies, Inc. Distinguishing rare variations in a nucleic acid sequence from a sample
JP6590810B2 (ja) 2013-12-24 2019-10-16 ヤンセン ファーマシューティカ エヌブイ 抗ｖｉｓｔａ抗体および断片
WO2015103367A1 (en) 2013-12-31 2015-07-09 Raindance Technologies, Inc. System and method for detection of rna species
EP3119876A1 (en) 2014-03-19 2017-01-25 Pfizer Inc. Method of cell culture
BR112016029076B1 (pt) 2014-06-12 2024-02-15 Ra Pharmaceuticals, Inc Polipeptídeo e composição compreendendo o mesmo para inibir a clivagem de c5 em um sistema celular
WO2015196128A2 (en) 2014-06-19 2015-12-23 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
CN114057857A (zh) 2014-06-20 2022-02-18 豪夫迈·罗氏有限公司 基于chagasin的支架组合物、方法和应用
AU2015289656A1 (en) 2014-07-16 2017-02-16 Modernatx, Inc. Circular polynucleotides
PL3250230T3 (pl) 2015-01-28 2022-02-14 Ra Pharmaceuticals, Inc. Modulatory aktywności dopełniacza
WO2016141111A1 (en) 2015-03-03 2016-09-09 Xoma (Us) Llc Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
JP6901400B2 (ja) 2015-04-03 2021-07-14 ゾーマ テクノロジー リミテッド ＴＧＦ−β及びＰＤ−１の阻害物質を使用する癌の治療法
CA2980189A1 (en) 2015-04-24 2016-10-27 Genentech, Inc. Multispecific antigen-binding proteins
CA2985138A1 (en) 2015-05-06 2016-11-10 Janssen Biotech, Inc. Prostate specific membrane antigen binding fibronectin type iii domains
BR112017027870A2 (pt) 2015-06-24 2018-08-28 Janssen Pharmaceutica Nv anticorpos e fragmentos anti-vista
US10253101B2 (en) 2015-08-06 2019-04-09 Xoma (Us) Llc Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia
US10647981B1 (en) 2015-09-08 2020-05-12 Bio-Rad Laboratories, Inc. Nucleic acid library generation methods and compositions
WO2017049286A1 (en) 2015-09-17 2017-03-23 Moderna Therapeutics, Inc. Polynucleotides containing a morpholino linker
WO2017051347A2 (en) 2015-09-23 2017-03-30 Pfizer Inc. Cells and method of cell culture
LT3389692T (lt) 2015-12-16 2020-04-27 Ra Pharmaceuticals, Inc. Komplemento aktyvumo moduliatoriai
WO2017137830A1 (en) 2016-02-12 2017-08-17 Janssen Pharmaceutica Nv Anti-vista (b7h5) antibodies
AU2017241776A1 (en) 2016-03-29 2018-10-11 Janssen Biotech, Inc. Treating psoriasis with increased interval dosing of anti-IL12 and/or -23 antibody
EP3440190A1 (en) 2016-04-05 2019-02-13 Pfizer Inc Cell culture process
WO2017175058A1 (en) 2016-04-07 2017-10-12 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
EP3463430A4 (en) 2016-06-03 2020-02-12 Janssen Biotech, Inc. SERUM ALBUMIN BINDING FIBRONECTIN TYPE III DOMAINS
WO2017223180A2 (en) 2016-06-21 2017-12-28 Janssen Biotech, Inc. Cysteine engineered fibronectin type iii domain binding molecules
EP3475446A1 (en) 2016-06-27 2019-05-01 Juno Therapeutics, Inc. Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
MA45491A (fr) 2016-06-27 2019-05-01 Juno Therapeutics Inc Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
JP2019524721A (ja) 2016-07-15 2019-09-05 ポセイダ セラピューティクス， インコーポレイテッド キメラ抗原受容体および使用方法
CN109715670A (zh) 2016-07-15 2019-05-03 波赛达治疗公司 对muc1特异性的嵌合抗原受体(car)及其使用方法
EP3490600A1 (en) 2016-08-01 2019-06-05 Xoma (Us) Llc Parathyroid hormone receptor 1 (pth1r) antibodies and uses thereof
CN109715199A (zh) 2016-09-14 2019-05-03 詹森生物科技公司 包含bcma特异性iii型纤连蛋白结构域的嵌合抗原受体及其用途
JP2019534710A (ja) 2016-09-28 2019-12-05 ゾーマ （ユーエス） リミテッド ライアビリティ カンパニー インターロイキン２に結合する抗体およびその使用
US20180094052A1 (en) 2016-09-30 2018-04-05 Janssen Biotech, Inc. Safe and Effective Method of Treating Psoriasis with Anti-IL23 Specific Antibody
MA46861A (fr) 2016-11-16 2019-09-25 Janssen Biotech Inc Procédé de traitement du psoriasis avec un anticorps anti-il-23 spécifique
BR112019011053A2 (pt) 2016-12-07 2019-10-15 Ra Pharmaceuticals Inc moduladores da atividade do complemento
EP3554561B1 (en) 2016-12-14 2023-06-28 Janssen Biotech, Inc. Cd137 binding fibronectin type iii domains
BR112019012154A2 (pt) 2016-12-14 2019-11-12 Janssen Biotech Inc domínios do tipo iii da fibronectina de ligação a cd8a
EP3554535A4 (en) 2016-12-14 2020-10-21 Janssen Biotech, Inc. PD-L1 BINDING FIBRONECTIN TYPE III DOMAINS
EP3354736B1 (en) * 2017-01-25 2020-07-01 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Promoter construct for cell-free protein synthesis
KR20240038146A (ko) 2017-01-30 2024-03-22 얀센 바이오테크 인코포레이티드 활성 건선성 관절염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
WO2018147915A1 (en) 2017-02-07 2018-08-16 Janssen Biotech, Inc. Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
IL269203B1 (en) 2017-03-13 2024-05-01 Poseida Therapeutics Inc Preparations and methods for the selective elimination and replacement of hematopoietic stem cells
JP7177076B2 (ja) 2017-03-16 2022-11-22 ファイザー・インク チロシン原栄養性
CN111727256A (zh) 2017-09-08 2020-09-29 波赛达治疗公司 用于嵌合配体受体（clr）-介导的条件性基因表达的组合物和方法
KR20200047702A (ko) 2017-09-15 2020-05-07 브리스톨-마이어스 스큅 컴퍼니 관심 폴리펩티드 대규모 생산 동안의 온라인 바이오매스 정전용량 모니터링
TW201922780A (zh) 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
WO2019150309A1 (en) 2018-02-02 2019-08-08 Hammack Scott Modulators of gpr68 and uses thereof for treating and preventing diseases
JP2021515770A (ja) 2018-03-05 2021-06-24 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ−２３特異的抗体を用いたクローン病の治療方法
US20210010055A1 (en) 2018-03-16 2021-01-14 Bristol-Myers Squibb Company Metabolic enzyme activity and disulfide bond reduction during protein production
JP2021523138A (ja) 2018-05-11 2021-09-02 ヤンセン バイオテツク，インコーポレーテツド Ｉｌ−２３抗体を使用してうつを治療する方法
WO2020016838A2 (en) 2018-07-18 2020-01-23 Janssen Biotech, Inc. Sustained response predictors after treatment with anti-il23 specific antibody
FI3883606T3 (fi) 2018-09-24 2023-09-07 Janssen Biotech Inc Turvallinen ja tehokas menetelmä haavaisen paksusuolitulehduksen hoitamiseksi anti-il12/il23-vasta-aineella
BR112021009287A2 (pt) 2018-11-20 2021-10-26 Janssen Biotech, Inc. Método seguro e eficaz para tratar psoríase com anticorpo específico anti-il-23
WO2020115655A1 (en) 2018-12-06 2020-06-11 Pfizer Inc. Cells with reduced inhibitor production and methods of use thereof
US20200197517A1 (en) 2018-12-18 2020-06-25 Janssen Biotech, Inc. Safe and Effective Method of Treating Lupus with Anti-IL12/IL23 Antibody
EP3898993A1 (en) 2018-12-20 2021-10-27 Poseida Therapeutics, Inc. Nanotransposon compositions and methods of use
AU2020208828A1 (en) 2019-01-15 2021-08-05 Janssen Biotech, Inc. Anti-TNF antibody compositions and methods for the treatment of juvenile idiopathic arthritis
EA202192038A1 (ru) 2019-01-23 2021-10-05 Янссен Байотек, Инк. Композиции антител к фно для применения в способах лечения псориатического артрита
CN113365661A (zh) 2019-01-31 2021-09-07 新加坡科技研究局 用于治疗或预防癌症的cnx/erp57抑制剂
WO2020183270A1 (en) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Methods for producing anti-tnf antibody compositions
EP3938384A4 (en) 2019-03-14 2022-12-28 Janssen Biotech, Inc. METHODS OF MANUFACTURING FOR PRODUCING ANTI-IL12/IL23 ANTIBODY COMPOSITIONS
US20220153830A1 (en) 2019-03-14 2022-05-19 Janssen Biotech, Inc. Manufacturing Methods for Producing Anti-TNF Antibody Compositions
CN113840837A (zh) 2019-03-14 2021-12-24 詹森生物科技公司 用于产生抗tnf抗体组合物的方法
WO2020188466A1 (en) 2019-03-18 2020-09-24 Janssen Biotech, Inc. Method of treating psoriasis in pediatric subjects with anti-il12/il23 antibody
CN113795514A (zh) 2019-05-09 2021-12-14 豪夫迈·罗氏有限公司 制备抗体的方法
AU2020279987A1 (en) 2019-05-23 2021-11-18 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
KR20220030952A (ko) 2019-06-03 2022-03-11 얀센 바이오테크 인코포레이티드 활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
CN113939531A (zh) 2019-06-03 2022-01-14 詹森生物科技公司 用于治疗银屑病关节炎的抗tnf抗体组合物和方法
WO2021028752A1 (en) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anti-tfn antibodies for treating type i diabetes
EP4025593A1 (en) 2019-09-05 2022-07-13 Poseida Therapeutics, Inc. Allogeneic cell compositions and methods of use
EP4045061A4 (en) 2019-10-14 2024-04-17 Aro Biotherapeutics Company FIBRONECTIN TYPE III DOMAINS BINDING TO CD137
US11781138B2 (en) 2019-10-14 2023-10-10 Aro Biotherapeutics Company FN3 domain-siRNA conjugates and uses thereof
WO2021127505A1 (en) 2019-12-20 2021-06-24 Poseida Therapeutics, Inc. Anti-muc1 compositions and methods of use
US20230121433A1 (en) 2020-03-11 2023-04-20 Poseida Therapeutics, Inc. Chimeric stimulatory receptors and methods of use in t cell activation and differentiation
CN115996747A (zh) 2020-04-14 2023-04-21 波赛达治疗公司 用于治疗癌症的组合物和方法
US20240000969A1 (en) 2020-10-21 2024-01-04 Poseida Therapeutics San Diego Compositions and methods for delivery of nucleic acids
CN117751138A (zh) 2021-03-12 2024-03-22 詹森生物科技公司 用抗il23特异性抗体治疗银屑病关节炎的安全且有效的方法
KR20230156764A (ko) 2021-03-12 2023-11-14 얀센 바이오테크 인코포레이티드 항-il23 특이적 항체에 의해 tnf 요법에 부적절한 반응을 보이는 건선성 관절염 환자를 치료하는 방법
EP4367138A1 (en) 2021-07-09 2024-05-15 Janssen Biotech, Inc. Manufacturing methods for producing anti-il12/il23 antibody compositions
US20230042465A1 (en) 2021-07-09 2023-02-09 Janssen Biotech, Inc. Manufacturing Methods for Producing Anti-TNF Antibody Compositions
KR20240034218A (ko) 2021-07-09 2024-03-13 얀센 바이오테크 인코포레이티드 항-tnf 항체 조성물을 생산하기 위한 제조 방법
WO2023060088A1 (en) 2021-10-04 2023-04-13 Poseida Therapeutics, Inc. Transposon compositions and methods of use thereof
WO2023073615A1 (en) 2021-10-29 2023-05-04 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
WO2023079058A1 (en) 2021-11-05 2023-05-11 Yokogawa Insilico Biotechnology Gmbh Cell culture with reduced production of lactate
US20230151087A1 (en) 2021-11-15 2023-05-18 Janssen Biotech, Inc. Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
US20230159633A1 (en) 2021-11-23 2023-05-25 Janssen Biotech, Inc. Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
WO2023141576A1 (en) 2022-01-21 2023-07-27 Poseida Therapeutics, Inc. Compositions and methods for delivery of nucleic acids
WO2023148598A1 (en) 2022-02-02 2023-08-10 Pfizer Inc. Cysteine prototrophy
WO2023187707A1 (en) 2022-03-30 2023-10-05 Janssen Biotech, Inc. Method of treating mild to moderate psoriasis with il-23 specific antibody
WO2023223265A1 (en) 2022-05-18 2023-11-23 Janssen Biotech, Inc. Method for evaluating and treating psoriatic arthritis with il23 antibody

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4710464A (en) * 1984-09-27 1987-12-01 Eli Lilly And Company Transcription terminators
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
ZA862335B (en) * 1985-03-28 1987-11-25 Cetus Corp Process for amplifying nucleic acid sequences
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
DE3590766C2 (ko) * 1985-03-30 1991-01-10 Marc Genf/Geneve Ch Ballivet
US4800159A (en) * 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences

Also Published As

Publication number Publication date
AU638762B2 (en) 1993-07-08
JP2001078787A (ja) 2001-03-27
US5643768A (en) 1997-07-01
DK0494955T3 (da) 1998-10-26
DE69032483D1 (de) 1998-08-20
KR100204360B1 (en) 1999-06-15
CA2067194A1 (en) 1991-04-06
CA2067194C (en) 2003-03-18
EP0494955A4 (en) 1992-08-12
ES2118066T3 (es) 1998-09-16
JPH05503000A (ja) 1993-05-27
KR0185192B1 (ko) 1999-04-01
EP0494955A1 (en) 1992-07-22
US5658754A (en) 1997-08-19
DE69032483T2 (de) 1998-11-26
ATE168416T1 (de) 1998-08-15
EP0494955B1 (en) 1998-07-15
WO1991005058A1 (en) 1991-04-18
KR100204359B1 (en) 1999-06-15
JP3127158B2 (ja) 2001-01-22
AU6537390A (en) 1991-04-28

Similar Documents

Publication Publication Date Title
KR920703839A (ko) 신규의 유전자 및 폴리펩티드의 무세포 합성 및 분리
US6312927B1 (en) Methods for producing nucleic acids lacking 3'-untranslated regions and optimizing cellular RNA-protein fusion formation
US6716973B2 (en) Use of a ribozyme to join nucleic acids and peptides
KR100713953B1 (ko) Ｒｎａ-단백질 융합체를 이용한 단백질의 선별
KR100566859B1 (ko) Ｒｎａ-단백질 융합물을 이용한 단백질의 선별
US6143503A (en) Use of a ribozyme to join nucleic acids and peptides
EP0590689B1 (fr) Procédé d'obtention d'ADN, ARN, peptides, polypeptides ou protéines, par une technique de recombinaison d'ADN
US7846694B2 (en) Process for producing template DNA and process for producing protein in cell-free protein synthesis system with the use of the same
JP6004399B2 (ja) 安定化された二次構造を有するペプチド、及びペプチドライブラリー、それらの製造方法
CN110637086B (zh) Rna分子与肽的复合体的制造方法及其利用
JP4519318B2 (ja) 連続的ｉｎｖｉｔｒｏ進化
RU99118585A (ru) Отбор белков с использованием рнк-пептидных гибридов
JPH09500007A (ja) 新規化合物生成に関するランダム化学
Zoller New recombinant DNA methodology for protein engineering
JPH0776596A (ja) ペプチド、融合ペプチド、発現ベクター及び組換えタンパク質の製造方法
JPH0669375B2 (ja) 特異的切断リンカ−
KR960705041A (ko) Tgf 수용체 족 및/ 또는 bmp 수용체 족에 속하는 액티빈 수용체 유사 키나제(alk) (activin receptors-like kinase (alk), belonging to the tgf receptor family and/or to the bmp receptor family)
WO2000018881A9 (en) Intein mediated peptide ligation
JPS5944399A (ja) 新規ｄｎａ
WO2003062417A1 (fr) Produit de ligation arn-adn, et utilisation correspondante
JP2019073511A (ja) アゾリン化合物及びアゾール化合物のライブラリー、並びにその製造方法
JPWO2020067550A1 (ja) 化合物ライブラリー及び化合物ライブラリーの製造方法
AU2004200998B2 (en) Methods for producing nucleic acids lacking 3'-untranslated regions and optimizing cellular RNA-protein fusion formation
JP4897265B2 (ja) 新規な非天然アミノ酸のタンパク質への導入法
JPS633790A (ja) プラスミド組換え体

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20090730

Year of fee payment: 12

EXPY Expiration of term